three-year
Sarepta Therapeutics Reports Positive Three-Year EMBARK Data for Elevidys in Duchenne Amid Past Safety Concerns
Sarepta; Elevidys; Duchenne muscular dystrophy; EMBARK trial; three-year data; gene therapy; patient deaths
Actionable Insights Powered by AI
Sarepta; Elevidys; Duchenne muscular dystrophy; EMBARK trial; three-year data; gene therapy; patient deaths